Pharmaceutical compounds for the treatment of complement mediated disorders

A compound of Formula (I):

• or a pharmaceutically acceptable salt thereof,
• wherein
• X1 is C or N;
• X2 is C, S, or Si;
• each of R1, R1′, R2, R2′, R3, and R3′ is independently selected from H, halo, hydroxy, optionally substituted C1-C6 alkyl, optionally substituted C3-C8 cycloalkyl, optionally substituted C6-C14 aryl, optionally substituted 5-to 10-membered heterocycle, or optionally substituted 5-to 10-membered heteroaryl;
• optionally substituted C1-C6 alkoxy;
• optionally substituted C6-C14 aryloxy, (optionally substituted 5-to 10-membered heteroaryl)oxy;
• SO2Ra, wherein Ra is H, C1-C6 alkyl, or C3-C8 cycloalkyl;
• S(O)(NH)Rb, wherein Rb is H or C1-C6 alkyl, wherein, when X1 is N, R8 or R1 is absent and when X2 is S, R2 and R2′ are absent;
• or
• R1 and R2, together with the atoms to which each is attached, form optionally substituted C3-C8 cycloalkyl;
• or
• R1 and R2 combine to form a double bond;
• R1 and R2′, together with the atoms to which each is attached, form optionally substituted C3-C8 cycloalkyl;
• or
• R2 and R2′, together with the atom to which they are attached, form optionally substituted 4-or 5-membered spirocyclic heterocycle;
• or
• R2 and R2′, together with the atom to which they are attached, form optionally substituted C3-C8 spirocyclic cycloalkyl;
• or
• R2 and R2′ combine to form=C(Rc)2, wherein each Rc is independently H or halo;
• Y is:
• wherein
• Y1 is O, S, NRd, wherein each Rd is independently absent, H, or C1-C6 alkyl;
• Y1′ is O, S, NRd, or C(Rd)2;
• each of Y2 and Y3 is independently NRe or C(Re)2, wherein each Re is independently absent;
• H;
• optionally substituted C1-C6 alkyl;
• halo;
• or N(Rg)2, wherein each Rg is independently H or C1-C6 alkyl;
• or both Re combine to form oxo;
• each of Y4, Y4′, Y10, and Y13 is independently CRe or N;
• each of Y5, Y6, and Y7 is independently O, S, NRf or C(Rf)2, wherein each Rf is independently absent;
• H;
• optionally substituted C1-C6 alkyl;
• halo;
• or N(Rg)2;
• or both Rf combine to form oxo;
• each of YR and Y is independently C(Rf)2 or NRf;
• each of Y11 and Y12 is independently NRe, C(Re)2, S, or O;
• each is independently a single bond or a double bond:
• each of R, R′, R″, and R′″ is independently absent, H, optionally substituted C1-C6 alkyl, halo, or N(Rg)2;
• or
• both R combine to form oxo;
• or
• both R1 combine to form oxo;
• and
• q is 0 or 1;
• L is selected from a bond,
• wherein R4 is H, CH3, CF3, or CH2OH;
• L1 is a bond or optionally substituted C1-C6 alkylene;
• L2 is a bond or O;
• B is optionally substituted C6-C14 aryl;
• optionally substituted C3-C14 carbocyclyl;
• optionally substituted 5-to 14-membered heterocyclyl;
• or optionally substituted 5-to 10-membered heteroaryl;
• and
• A is H or C1-C6 alkyl;
• or
• A is optionally substituted C1-C2 alkylene bound to a ring atom in B.